MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow dips below year-ago levels
Q3 FY2026 financing cash flow of $99.61M fell 47.0% year over year, behind the +0.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 4191.8% from the prior quarter. Over 3 fiscal years it compounded at +60.3% a year.
Context
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -47.0% toward the trailing-twelve-month pace of +0.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 189.59M USD
- Year-over-year change
- -19.0%
- 3-year CAGR
- +60.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 189.59M | -19.0% |
| FY2024 | 2024-12-31 | 234.1M | +238.2% |
| FY2023 | 2023-12-31 | 69.22M | +50.3% |
| FY2022 | 2022-12-31 | 46.06M | — |
Financing Cash Flow vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.4% is the 5th highest of 8, against a peer median of +363.0%.
- Over three fiscal years its annual growth of +60.3% compares with a peer median of +27.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | FY2025 | $598.66M USD | — | — | — |
| LTM Mar 2026 | $251.49M USD | +466.1% | +53.9% | 698594.4% | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $189.81M USD | +0.4% | +60.3% | — |
| LTM Sep 2026 | €113.07M EUR | -505.3% | -55.5% | 9.4% | |
| LTM Jun 2026 | $111.25M USD | +2441.0% | +163.8% | — | |
| LTM Mar 2026 | $64.53M USD | +1243.2% | +279.8% | — | |
| LTM Sep 2026 | $15.76M USD | -106.1% | +0.6% | 5.6% | |
| LTM Mar 2026 | $15.14M USD | -54.2% | — | — | |
| LTM Mar 2026 | $5.69M USD | +363.0% | -55.3% | 1.8% | |
| Peer median (excluding MBX) | — | +363.0% | +27.3% | 7.5% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 306K | 2.04M | 5.22M | 8.68M |
| Change in Working Capital | 1.29M | (735K) | 4.6M | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 671K | 412K | 3.93M | (2.46M) |
| Other Working Capital | 619K | (1.15M) | 670K | 4.03M |
| Other Non-Cash Items | 1.36M | (880K) | (2.82M) | (3.48M) |
| Operating Cash Flow | (23.12M) | (31.98M) | (54.68M) | (79.95M) |
| Capital Expenditures | (441K) | (129K) | (874K) | (1.93M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.22M) | (63.8M) | (239.47M) | (358.15M) |
| Sales of Investments | 9.25M | 33M | 79.75M | 267.87M |
| Other Investing Activities | 0 | 0 | 0 | 8.5M |
| Investing Cash Flow | (11.41M) | (30.93M) | (160.6M) | (83.71M) |
| Debt Repayment | 10M | 0 | 0 | 0 |
| Common Stock Issued | 30K | 739K | 174.54M | 189.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (428K) | (30K) | (3.94M) | 0 |
| Financing Cash Flow | 46.06M | 69.22M | 234.1M | 189.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.53M | 6.31M | 18.83M | 25.94M |
| Free Cash Flow | (23.56M) | (32.11M) | (55.56M) | (81.88M) |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.